Pressure BioSciences (OTCQB: PBIO) has announced that it will be presenting at both the Benzinga Healthcare Conference and the Emerging Growth Small Cap Conference. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries. During the two conferences, which are real-time, interactive investor conferences, up-and-coming, innovative small-cap companies will be presenting. Representing Pressure BioSciences at the conferences will be PBIO president and CEO Richard T. Schumacher, who will present a corporate overview. The overview will include a discussion of PBIO’s resurgent revenue growth in 2021, the potential impact of the anticipated commercial release of its revolutionary Ultra Shear Technology(TM) platform, its impending acquisition of assets of a global ecofriendly agrochemicals company and its planned uplist to a U.S. national stock exchange. Schumacher’s Emerging Growth Conference presentation is scheduled for Wednesday, Sept. 29, 2021, at 10:30 a.m. EDT; the presentation will be available over a video webcast. The Benzinga conference presentation is scheduled for Thursday, Sept. 30, 2021, at 10:30 a.m. EDT, and will also be via video webcast.
To view the full Emerging Growth presentation, visit https://ibn.fm/GNOj5
To view the full Benzinga Healthcare Small Cap presentation, visit https://ibn.fm/qev18
To view the full press release, visit https://ibn.fm/uDq2h
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
